Education
About Us
Working with TipRanks
Follow Us
Fennec Pharmaceuticals (FENC)
NASDAQ:FENC
Earnings Data
Report Date
Aug 07, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.04Last Year’s EPS
-0.2Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 13, 2025
|% Change Since: -8.87%
|Next Earnings Date:Aug 07, 2025
Earnings Call Sentiment|Positive
The earnings call reflects a positive outlook with strong revenue growth, successful international expansion, and strategic advancements in targeting and adoption. However, challenges remain in managing cash burn and improving patient adherence.Company Guidance
During the first quarter of 2025, Fennec Pharmaceuticals reported net product sales of approximately $8.8 million, marking an 18% growth compared to the same period in 2024 and an 11% increase over the fourth quarter of 2024. The company focused on enhancing field execution and supporting sustainable growth in key PEDMARK segments, achieving early traction in top-tier targets such as Tampa General Hospital and City of Hope. Fennec estimates that approximately 20,000 cisplatin chemotherapy patients are treated annually in the AYA segment, a market larger than the pediatric segment. Operating expenses were detailed with selling and marketing expenses at $2.9 million and G&A expenses at $6.1 million for the quarter. Cash and cash equivalents stood at $22.6 million, with an expected full-year cash operating expense of approximately $33 million. The company also highlighted progress in international markets, with recent PEDMARK launches in Germany, the UK, and Scotland, and ongoing trials in Japan.Strong Revenue Growth
Fennec Pharmaceuticals reported net product sales of approximately $8.8 million for Q1 2025, reflecting an 18% growth compared to the same period last year and an 11% increase over Q4 2024.
Expansion of PEDMARK
PEDMARK is now launched commercially in Germany and the UK, with recent acceptance for use in Scotland. This marks important steps for Fennec's mission to expand access in the European Union and the UK.
Strategic Targeting and Adoption
The implementation of a sophisticated targeting model led to early traction with tier 1 targets and expanded PEDMARK's adoption into key institutions like Tampa General Hospital and City of Hope.
Positive Momentum in AYA Segment
Significant adoption and interest in the adolescent and young adult (AYA) segment, with 20,000 cisplatin chemotherapy patients treated annually in key tumor types.
Reduction in Selling and Marketing Expenses
Selling and marketing expenses decreased to $2.9 million in Q1 2025, down from $5.2 million in Q1 2024, due to the elimination of European pre-commercialization activities.
---
FENC Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
FENC Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Mar 10, 2025 | $6.88 | $6.11 | -11.19% |
Nov 07, 2024 | $4.95 | $4.36 | -11.92% |
Aug 13, 2024 | $6.25 | $5.85 | -6.40% |
May 14, 2024 | $10.02 | $7.34 | -26.75% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Fennec Pharmaceuticals (FENC) report earnings?
Fennec Pharmaceuticals (FENC) is schdueled to report earning on Aug 07, 2025, TBA Not Confirmed.
What is Fennec Pharmaceuticals (FENC) earnings time?
Fennec Pharmaceuticals (FENC) earnings time is at Aug 07, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is FENC EPS forecast?
FENC EPS forecast for the fiscal quarter 2025 (Q2) is -0.04.
---